Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Esophageal Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT02513563 2026-02-19

AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

Phase 2 Completed

42 enrolled 12 charts

Thoracic

Lung Neoplasms

NCT04837716 2026-02-19

Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

Phase 1 Active not recruiting

12 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04892953 2026-02-19

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

Phase 2 Recruiting

51 enrolled

Thoracic

Lung Neoplasms

NCT05403723 2026-02-19

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

Phase 1 Suspended

50 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07420439 2026-02-19

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

Phase 2 Not yet recruiting

108 enrolled

Lung Diseases, Interstitial

NCT03263650 2026-02-17

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

Phase 2 Active not recruiting

96 enrolled

Genitourinary

Prostate Cancer, Hereditary, 7, Prostatic Neoplasms

NCT06291064 2026-02-17

TARMAC

Phase 2 Recruiting

85 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06528691 2026-02-17

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

Phase 2 Recruiting

52 enrolled

CNS

Glioma, Central Nervous System Neoplasms

Clinical Trials

PROTECT

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

SJATRT

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

I-SPY

Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro

6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

ANTELOPE

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer

TELESCOPE

(NeoScorch HN)

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

PREDICT

Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

APG-115 in Salivary Gland Cancer Trial

Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

HIPEC

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

Opti-HER2

Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

NIRVANA-LUNG

PRISM-TNBC

Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

TARMAC

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors